Gemcitabine: 5 agencies, 2004–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 20.7 years separate the first record, 1 Nov 2004 at PHARMAC (New Zealand), from the most recent, 2025 at PBAC (Australia).
PHARMAC (New Zealand) changed its position: recommended on 1 Nov 2004, restricted by 24 Sep 2020.
No assessment is on file from SMC (Scotland), TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
3 distinct indication wordings are recorded for gemcitabine by the agencies that label one in English (AWMSG, NICE and PBAC).
1 of these 17 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
PHARMAC (New Zealand) was first to assess gemcitabine, on 1 Nov 2004; PBAC (Australia) did not open a file until 2025 — an unusually long tail of 20.7 years between the earliest and latest system to look at it.
The record arrives in waves: 6 separate years each carry two or more decisions, spread across 10 years in total.
2 of the 5 agencies here assessed gemcitabine more than once, HAS (France) most often at 10 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 5 of the 18 agencies here have assessed gemcitabine.
The full ledger for gemcitabine reads 14 recommended, 1 restricted, 1 not recommended and 1 deferred to NICE.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2025 | Various cancers | Recommended | source |
| PHARMAC (New Zealand) | 24 Sep 2020 | Adjuvant pancreatic cancer | PTAC advice: Low · decision reached | source |
| HAS (France) | 16 Sep 2020 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| NICE (England) | 24 Jan 2007 | NICE TA116 | recommended | source |
| AWMSG (Wales) | 24 Jan 2007 | Treatment of patients with metastatic breast cancer, in combination with paclitaxel, who have relapsed following adjuvan… | excluded, NICE appraised | source |
12 further decisions for gemcitabine, across 2 agencies, are not shown here. They link to 11 further source documents.
Related molecules
- pemetrexed — same ATC class L01B — Antineoplastics
- azacitidine — same ATC class L01B — Antineoplastics
- capecitabine — same ATC class L01B — Antineoplastics
- cytarabine — same ATC class L01B — Antineoplastics
- fluorouracile — same ATC class L01B — Antineoplastics
- clofarabine — same ATC class L01B — Antineoplastics
Coverage: 17 decisions for gemcitabine from 5 agencies, 2004 to 2025. Data to 7 Sep 2026. ATC class L01B — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.